TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

Adv Ther. 2023 Apr;40(4):1317-1333. doi: 10.1007/s12325-022-02421-w. Epub 2023 Jan 23.

Abstract

TMPRSS6 is a serine protease highly expressed in the liver. Its role in iron regulation was first reported in 2008 when mutations in TMPRSS6 were shown to be the cause of iron-refractory iron deficiency anemia (IRIDA) in humans and in mouse models. TMPRSS6 functions as a negative regulator of the expression of the systemic iron-regulatory hormone hepcidin. Over the last decade and a half, growing understanding of TMPRSS6 biology and mechanism of action has enabled development of new therapeutic approaches for patients with diseases of erythropoiesis and iron homeostasis.ClinicalTrials.gov identifier NCT03165864.

Keywords: Hemochromatosis; Ineffective erythropoiesis; Iron overload; Iron restriction; Thalassemia.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Iron-Deficiency* / drug therapy
  • Animals
  • Erythropoiesis* / genetics
  • Homeostasis
  • Humans
  • Iron / metabolism
  • Liver / metabolism
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Serine Endopeptidases / genetics
  • Serine Endopeptidases / metabolism

Substances

  • Iron
  • TMPRSS6 protein, human
  • Membrane Proteins
  • Serine Endopeptidases

Associated data

  • ClinicalTrials.gov/NCT03165864